ELEVATE-TN Study. New data of acalabrutinib in first-line treatment of chronic lymphocytic leukemia. Resolution

ELEVATE-TN Study. New data of acalabrutinib in first-line treatment of chronic lymphocytic leukemia. Resolution

Over the past decade, we have seen a significant change in modern approaches in the first-line treatment of chronic lymphocytic leukemia (CLL). The CLL-10 study data established the FCR regimen as the treatment of choice for younger patients with limited comorbidities, while for patients older than...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Irina V. Poddubnaya, Lyubov S. Al-Radi, Tatyana E. Byalik, Kamil D. Kaplanov, Valentina Z. Molostvova, Evgeniy A. Nikitin, Tatyana I. Pospelova, Vadim V. Ptushkin, Olga S. Samoilova, Elena A. Stadnik, Gayane S. Tumyan
Formato: article
Lenguaje:RU
Publicado: IP Habib O.N. 2020
Materias:
chronic lymphocytic leukemia
bruton’s tyrosine kinase inhibitors
immunochemotherapy
targeted therapy
acalabrutinib
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/67aed2307be24cdebf0808eebbc30d52
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/67aed2307be24cdebf0808eebbc30d52

Ejemplares similares